Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $138,910.58 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 12,946 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $10.73, for a total value of $138,910.58. Following the sale, the executive vice president now directly owns 722,128 shares in the company, valued at $7,748,433.44. The trade was a 1.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The shares were sold at an average price of $11.42, for a total value of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total value of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Stock Up 3.4 %

Alphatec stock opened at $12.53 on Friday. The business has a fifty day moving average of $10.63 and a two-hundred day moving average of $8.37. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm has a market cap of $1.78 billion, a P/E ratio of -9.79 and a beta of 1.43. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $14.88.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Alphatec

Hedge funds have recently bought and sold shares of the stock. Comerica Bank lifted its holdings in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares during the period. R Squared Ltd purchased a new stake in Alphatec during the fourth quarter worth $29,000. Nisa Investment Advisors LLC lifted its holdings in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares during the period. Quarry LP lifted its holdings in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after purchasing an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC purchased a new stake in shares of Alphatec during the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Piper Sandler upped their target price on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a research note on Friday. Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.